Review Article
Advanced, Neglected Basal Cell Carcinoma
Abstract
Although basal cell carcinoma (BCC) rarely metastasizes and has a cure rate 995% when diagnosed early in its course, BCC causes significant morbidity and presents an enormous burden to the healthcare system worldwide. Patients who present late in the course of their disease are particularly challenging in that their treatment can be more complicated and less likely to be effective than had they presented earlier. Given the high prevalence of this malignancy and the morbidity associated with a late presentation, healthcare professionals should be familiar with the consequences of neglected BCCs, as well as their management after presentation. Knowledge of patient risk characteristics may allow earlier engagement and diagnosis of patients, before more significant morbidity occurs.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994;30:774-778.
2. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006;19:S127-S147.
3. Goldsmith LA, Fitzpatrick TB. Fitzpatrick’s Dermatology in General Medicine. 8th ed. New York: McGraw-Hill Medical, 2012.
4. Bolognia J, Jorizzo JL, Schaffer JV. Dermatology. 3rd ed. Philadelphia: Elsevier Saunders; 2012.
5. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003;327:794-798.
6. Firnhaber JM. Diagnosis and treatment of basal cell and squamous cell carcinoma. Am Fam Physician 2012;86:161-168.
7. Chen J, Ruczinski I, Jorgensen TJ, et al. Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst 2008;100:1215-1222.
8. Randle HW. Basal cell carcinoma. Identification and treatment of the high-risk patient. Dermatol Surg 1996;22:255-261.
9. Lever WF, Elder DE. Lever’s Histopathology of the Skin. 10th ed.Philadelphia: Lippincott Williams & Wilkins, 2009.
10. Husein-Elahmed H, Gutierrez-Salmeron MT, Naranjo-Sintes R, et al. Factors related to delay in the diagnosis of basal cell carcinoma. J Cutan Med Surg 2013;17:27-32.
11. Blackford S, Roberts D, Salek MS, et al. Basal cell carcinomas cause little handicap. Qual Life Res 1996;5:191-194.
12. Antoszewski B, Kasielska A, Fijaakowska M. Face skin neoplasmsVreasons for delayed treatment. Pol Przegl Chir 2011;83:361-366.
13. Habif TP.Clinical Dermatology: AColor Guide to Diagnosis and Therapy. 5th ed. Edinburgh: Mosby Elsevier, 2010.
14. Bastiaens MT, ter Huurne JA, Kielich C, et al. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet 2001;68:884-894.
15. Gudbjartsson DF, Sulem P, Stacey SN, et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma.Nat Genet 2008;40:886-891.
16. Shamanin V, zur Hausen H, Lavergne D, et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 1996;88:802-811.
17. Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999;354:723-729.
18. Doherty VR, MacKie RM. Reasons for poor prognosis in British patients with cutaneous malignant melanoma. Br Med J (Clin Res Ed) 1986;292:987-989.
19. Alam M, Goldberg LH, Silapunt S, et al. Delayed treatment and continued growth of nonmelanoma skin cancer. J Am Acad Dermatol 2011;64:839-848.
20. Moyer A, Levine EG. Clarification of the conceptualization and measurement of denial in psychosocial oncology research. Ann Behav Med 1998;20:149-160.
21. Varga E, Korom I, Rasko´ Z, et al. Neglected basal cell carcinomas in the 21st century. J Skin Cancer 2011;2011:392151.
22. Grange F, Barbe C, Aubin F, et al. Clinical and sociodemographic characteristics associated with thick melanomas: a population-based, case-case study in France. Arch Dermatol 2012:1-7.
23. US Preventive Services Task Force. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:188-193.
24. Sobanko JF, Lynm C, Rosenbach M. Basal cell carcinoma. JAMA Dermatol 2013;149:766.
25. Kisely S, Crowe E, Lawrence D. Cancer-related mortality in people with mental illness. JAMA Psychiatry 2013;70:209-217.
26. Pavlou MP, Lachs MS. Could self-neglect in older adults be a geriatric syndrome? J Am Geriatr Soc 2006;54:831-842.
27. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999;135:1177-1183.
28. Chren MM, Linos E, Torres JS, et al. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2013;133:1188-1196.
29. MacFarlane DF, Pustelny BL, Goldberg LH. An assessment of the suitability of Mohs micrographic surgery in patients aged 90 years and older. Dermatol Surg 1997;23:389Y392.
30. Charles AJ, Otley CC, Pond GR. Prognostic factors for life expectancy in nonagenarians with nonmelanoma skin cancer: implications for selecting surgical candidates. J Am Acad Dermatol 2002;47:419-422.
31. Delaney A, Shimizu I, Goldberg LH, et al. Life expectancy after Mohs micrographic surgery in patients aged 90 years and older. J Am Acad Dermatol 2013;68:296-300.
32. Wax MK, Burkey BB, Bascom D, et al. The role of free tissue transfer in the reconstruction of massive neglected skin cancers of the head and neck. Arch Facial Plast Surg 2003;5:479-482.
